• 1
    Campbell WC. Ivermectin and Abamectin. New York , NY : Springer-Verlag; 1989.
  • 2
    Campbell WC, Fisher MH, Stapley EO, et al. Ivermectin: A potent new antiparasitic agent. Science 1983;221:823827.
  • 3
    Plumb DC. Veterinary Drug Handbook, 2nd ed. Ames , IA : Iowa State University Press; 1995.
  • 4
    Fassler PE, Tranquilli WJ, Paul AJ, et al. Evaluation of the safety of ivermectin administered in a beef-based formulation to ivermectin-sensitive Collies. JAVMA 1991;199:457460.
  • 5
    Paul AJ, Tranquilli WJ, Seward RL, et al. Clinical observations in Collies given ivermectin orally. Am J Vet Res 1987;48:684685.
  • 6
    Pulliam JD, Seward RL, Henry RT, Steinberg SA. Investigating ivermectin toxicity in Collies. Vet Med 1985;80:3340.
  • 7
    Easby SM. Ivermectin in the dog. Vet Rec 1984; 115: 45 (letter to the editor).
  • 8
    Sivine F. Picrotoxin, the antidote to ivermectin in dogs Vet Rec 1985; 116: 195 (letter to the editor).
  • 9
    Smith RA, Stronski EJ, Beck BE. Death of a Rough Collie exposed to an ivermectin-based paste. Can Vet J 1990; 31: 221 (letter to the editor).
  • 10
    Heit JE, Tranquilli WJ, Parker AJ, et al. Clinical management of ivermectin overdose in a collie dog. Companion Anim Pract 1989; 19:37.
  • 11
    Hopkins KD, Marcella KL, Strecker AE. Ivermectin toxicosis in a dog. JAVMA 1990;197:9394.
  • 12
    Hadrick MK, Bunch SE, Kornegay JN. Ivermectin toxicosis in two Australian Shepherds. J Am Vet Med Assoc 1995;206:11471152.
  • 13
    Drakulovic MB, Torres A, Bauer T, et al. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: A randomised trial. Lancet 1999;354:18511858.
  • 14
    Wang CC, Pong SS. Actions of avermectin B1a on GABA nerves. Prog Clin Biol Res 1982;97:375395.
  • 15
    Pong SS, Wang CC. Avermectin B1a modulation of γ-amino-butyric acid receptors in rat brain membranes. J Neurochem 1982;38:375379.
  • 16
    Pong SS, Wang CC, Fritz LC. Studies on the mechanism of action of avermectin B1a: Stimulation of release of γ-aminobutyric acid from brain synaptosomes. J Neurochem 1980;34:351357.
  • 17
    Goldstein GW, Betz AL. The blood-brain barrier. Sci Am 1986; 255:7483.
  • 18
    Schinkel AH, Smit JJM, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491502.
  • 19
    Tatsuta T, Naito M, Oh-hara T, et al. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 1992;267:2038320391.
  • 20
    Goodman GilmanA, ed. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. New York , NY : Pergamon Press; 1990.
  • 21
    Mellin TN, Busch RD, Wang CC. Postsynaptic inhibition of invertebrate neuromuscular transmission by avermectin B1a. J Neuro-pharmacol 1983;22:8996.
  • 22
    Tranquilli WJ, Paul AJ, Seward RL, et al. Response to physo-stigmine administration in collie dogs exhibiting ivermectin toxicosis. J Vet Pharmacol Ther 1987; 10:96100.